Twin Tree Management LP Takes Position in Zoetis Inc. (ZTS)
Twin Tree Management LP bought a new stake in Zoetis Inc. (NYSE:ZTS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,060 shares of the company’s stock, valued at approximately $191,000.
Other institutional investors have also added to or reduced their stakes in the company. Gladstone Capital Management LLP bought a new position in Zoetis in the second quarter valued at $3,134,000. Swiss National Bank grew its position in Zoetis by 8.1% in the second quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after purchasing an additional 133,900 shares in the last quarter. Harbour Capital Advisors LLC grew its position in Zoetis by 19.8% in the first quarter. Harbour Capital Advisors LLC now owns 20,005 shares of the company’s stock valued at $1,068,000 after purchasing an additional 3,300 shares in the last quarter. Hermes Investment Management Ltd. grew its position in Zoetis by 80.3% in the second quarter. Hermes Investment Management Ltd. now owns 236,350 shares of the company’s stock valued at $14,744,000 after purchasing an additional 105,276 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in Zoetis by 8.2% in the second quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after purchasing an additional 389,260 shares in the last quarter. 93.31% of the stock is owned by institutional investors and hedge funds.
Zoetis Inc. (NYSE ZTS) traded down 0.23% during mid-day trading on Friday, hitting $64.70. 2,608,157 shares of the stock were exchanged. The company has a market capitalization of $31.65 billion, a PE ratio of 36.57 and a beta of 1.02. The stock’s 50-day moving average is $61.87 and its 200 day moving average is $58.97. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $65.12.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.49 earnings per share. On average, analysts anticipate that Zoetis Inc. will post $2.34 EPS for the current year.
A number of research analysts recently weighed in on the stock. Cowen and Company set a $70.00 target price on shares of Zoetis and gave the company a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and raised their target price for the company from $64.00 to $65.00 in a research report on Tuesday, June 13th. They noted that the move was a valuation call. Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research report on Monday, August 14th. CL King started coverage on shares of Zoetis in a research report on Friday, May 26th. They issued a “buy” rating and a $71.00 price objective for the company. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company’s stock. Zoetis has a consensus rating of “Buy” and a consensus price target of $65.44.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.